Skip to main content

Del Carmen Jeffrey's Form 4 filing

Catalyst Pharmaceuticals, Inc. (CPRX) · filed Aug 22, 2022

Accession no.
0001161697-22-000405
Filed
Aug 22, 2022
Trade date
Aug 19, 2022
Filing delay
3 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 1 non-derivative transaction. Open-market sales total $198.7K. It was filed 3 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Del Carmen JeffreyCIK 0001816477Officer (Chief Commercial Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 19, 2022Common stock, par value $0.001 per shareSSaleAcquired+14,140$14.05F1,F2+$198,6670Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Shares were sold in various lots from $14.00 to $14.23 per share. The listed sales price represents a weighted average price for the shares sold.

Referenced by the price of 1 transaction in Table I.

F2

Shares were sold for personal reasons, and does not relate to any disagreements with the Company. Mr. Del Carmen remains an officer of the Company.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)